Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748722 | 0.87 | MAPT (0.61) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL6901999 | 0.85 | MEN1 (0.51) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL12302089 | 0.83 | HPGD (0.56) | HPGDMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL1019188 | 0.82 | KAT6A (0.51) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL6746948 | 0.82 | KMT2A (0.49) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL12818997 | 0.82 | MAPT (0.49) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL11544239 | 0.81 | HPGD (0.50) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL29082358 | 0.80 | MEN1 (0.51) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL16870481 | 0.80 | MAPT (0.48) | HPGDMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL14357551 | 0.80 | ALDH1A1 (0.56) | HPGDMEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362190-A | Preparation method of polysubstituted olefin | 广东工业大学 | 2024-01-09 | — | — | CN | disclosed |
| CN-112521560-B | Efficient salt-resistant one-dose dual-purpose thickening agent and preparation method and application thereof | 西安长庆化工集团有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-10646850-B2 | Material for blood purification | TORAY INDUSTRIES, INC. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-20190184371-A1 | MATERIAL FOR BLOOD PURIFICATION | TORAY INDUSTRIES, INC. (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC. | 2017-07-06 | — | — | US | disclosed |
| US-RE42375-E1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1340744-B1 | Hiv protease inhibitors | AGOURON PHARMA (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| EP-0652009-A1 | Identification and use of protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0609625-A1 | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1994-08-10 | — | — | EP | disclosed |
| WO-1994015906-A1 | HIV PROTEASE INHIBITORS AND THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994015608-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| EP-0604184-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604186-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604182-A2 | Inhibitors of HIV protease useful for the treatment of Aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604183-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0526009-A1 | Inhibitors of hiv protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | KLK3, FOLH1, UTS2R | HPGD 2565/4885MEN1 411/4885KMT2A 3241/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | HPGD 3453/4885MEN1 213/4885KMT2A 2669/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | HPGD 449/4885MEN1 3743/4885KMT2A 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.